PrzemyslawTwardowskiMD

Genitourinary Oncology, Hematologic Oncology

Professor of Medical Oncology and Urologic Oncology , Director of Clinical Research, John Wayne Cancer Institute, Santa Monica , CA

Join to view full profile

Dr. Twardowski is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Twardowski's full profile

Already have an account?

Office
2121 Santa Monica Blvd
Santa Monica, CA 90404
Phone+1 310-582-7137

Fax+1 310-582-7140

Education & Training

McGaw Medical Center of Northwestern UniversityFellowship, Hematology and Medical Oncology, 1994 - 1997
McGaw Medical Center of Northwestern UniversityFellowship, Hematology and Medical Oncology, 1993 - 1994
McGaw Medical Center of Northwestern UniversityResidency, Internal Medicine, 1990 - 1993
University of Missouri-Columbia School of MedicineClass of 1990

Certifications & Licensure

CA State Medical License 1998 - 2026
IL State Medical License 1990 - 1999
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2010-2014
Top Doctors:LA Area Castle Connolly, 2013
America's Top Doctors for Cancer Castle Connolly, 2009-2013
Top Doctors:Southern California Castle Connolly, 2012
Join now to see all

Clinical Trials

SU5416 and Paclitaxel in Treating Patients With Advanced Cancer Start of enrollment: 2000 Nov 01
Completed
Phase 1
Arsenic Trioxide and Pamidronate in Treating Patients With Advanced Solid Tumors or Multiple Myeloma Start of enrollment: 2005 Apr 01
Completed
Phase 1
Eribulin Mesylate in Treating Patients With Locally Advanced or Metastatic Cancer of the Urothelium and Kidney Dysfunction Start of enrollment: 2006 Oct 23
Active, not recruiting
Phase 1, Phase 2
Hormone Therapy and Intensity-Modulated Radiation Therapy in Treating Patients With Metastatic Prostate Cancer Start of enrollment: 2006 Jul 18
Active, not recruiting
Phase 2
Etoposide and Celecoxib in Patients With Advanced Cancer Start of enrollment: 2001 Dec 01
Completed
Phase 1
Cyclophosphamide and Celecoxib in Treating Patients With Advanced Cancer Start of enrollment: 2001 Sep 01
Completed
Phase 1
White Button Mushroom Extract in Treating Patients With Recurrent Prostate Cancer After Local Therapy Start of enrollment: 2009 Jan 29
Completed
Phase 1
First-Line Gemcitabine, Cisplatin + Ipilimumab for Metastatic Urothelial Carcinoma Start of enrollment: 2012 Jan 01
Completed
Phase 2
Abiraterone Acetate and Prednisone With or Without Veliparib in Treating Patients With Metastatic Castration-Resistant Prostate Cancer Start of enrollment: 2012 Mar 30
Completed
Phase 2
Trebananib With or Without Bevacizumab, Pazopanib Hydrochloride, Sorafenib Tosylate, or Sunitinib Malate in Treating Patients With Advanced Kidney Cancer Start of enrollment: 2012 Aug 01
Completed
Phase 2
Sipuleucel-T With or Without Radiation Therapy in Treating Patients With Hormone-Resistant Metastatic Prostate Cancer Start of enrollment: 2013 Jun 07
Completed
Phase 2
S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer Start of enrollment: 2013 Mar 08
Active, not recruiting
Phase 3
Fluorine F 18 Sodium Fluoride PET/CT and Whole Body and Axial MRI in Finding Metastases in Patients With Recurrent Prostate Cancer Start of enrollment: 2013 Dec 01
Completed
Not Applicable
A Phase II Study of Androgen Deprivation Therapy With or Without Palbociclib in RB-Positive Metastatic Prostate Cancer Start of enrollment: 2014 Jun 01
Completed
Phase 2
Join now to see all

Publications & Presentations

PubMed

209 citations
Prostate Cancer, Version 3.2012 Featured Updates to the NCCN Guidelines
James L. Mohler, Andrew J. Armstrong, Robert R. Bahnson, Barry Boston, J. Erik Busby
Journal of the National Comprehensive Cancer Network. 2012-09-01
404 citations
Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer.
Maha Hussain, Joaquin Mateo, Karim Fizazi, Fred Saad, Neal D. Shore
The New England Journal of Medicine. 2020-09-20
44 citations
A phase II trial of dasatinib in patients with metastatic castration-resistant prostate cancer treated previously with chemotherapy
Przemyslaw Twardowski, Jan H. Beumer, Chien-Shing Chen, Andrew S. Kraft, Gurkamal Chatta
Anti-Cancer Drugs. 2013-08-01

Journal Articles

Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer
Maha Hussain, Neeraj Agarwal, Przemyslaw Twardowski, The New England Journal of Medicine

Press Mentions

Advanced Prostate Cancer: Experts Say This Double Therapy Can HelpMarch 30th, 2023
Prostate Cancer ADT Has Fewer Cardiovascular Risks Than ExpectedJanuary 12th, 2022
25 Warning Signs Your Kidneys Send YouJune 8th, 2020
Join now to see all

Grant Support

Biologic Markers Of Angiogenesis: A Companion Study To "Phase I Trial Of OralNational Center For Research Resources2005
Phase I Trial Of Oral Cyclophosphamide With CelecoxibNational Center For Research Resources2004
Phase I Trial Of Etoposide In Combination W/ CelecoxibNational Center For Research Resources2004

Professional Memberships

American Society of Clinical Oncology - ASCO
Member